Health
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 | NEJM – nejm.org
Correspondence from The New England Journal of Medicine — SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
We conducted a global, randomized, placebo-controlled, phase 123 pivotal trial in which two 30-g doses of BNT162b2 (PfizerBioNTech) were administered 21 days apart (ClinicalTrials.gov number, NCT04368728). These doses of vaccine had mainly low-grade side…
Continue Reading
-
Noosa News22 hours agoPolice appeal for information over suspected link in torture and murder cases
-
Noosa News17 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News16 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General20 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline